Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.62 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7056507 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL2341258 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL5325207 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL2341262 | 1.00 | ADRB3 (0.62) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL7060452 | 0.95 | ADRB3 (0.64) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL8416006 | 0.94 | ADRB3 (0.63) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL7055661 | 0.92 | ADRB3 (0.63) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL7055665 | 0.92 | ADRB3 (0.63) | ADRB3ADRB1ADRB2ADRA1DADRA1A | |
| SCHEMBL3698875 | 0.91 | ADRB3 (0.52) | ADRB3ADRB1ADRB2CYP2D6 | |
| SCHEMBL7055926 | 0.91 | ADRB3 (0.57) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | claimed |
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | MEDICINOVA, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1806335-A1 | METHOD FOR PRODUCING PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064758-A1 | METHOD OF TREATMENT OR PROPHYLAXIS OF DEPRESSION | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB1 3/4885ADRB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.